Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

In my previous analysis of Altimmune, Inc. (NASDAQ: ALT ) in April 2024, I underscored the promising potential of its lead drug candidate, Pemvidutide [ALT-801]. This candidate is now quickly becoming an exciting complete treatment for obesity and metabolic-associated liver disease [MASLD/MASH]. Its GLP-1/glucagonMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science ...